» Articles » PMID: 3260765

Comparison of Dosages, Intervals, and Drugs in the Prevention of Pneumocystis Carinii Pneumonia

Overview
Specialty Pharmacology
Date 1988 May 1
PMID 3260765
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The efficacies of trimethoprim (TMP)-sulfamethoxazole (SMZ), TMP-dapsone, dapsone, and pentamidine were compared for the prevention of Pneumocystis carinii pneumonia in the corticosteroid-treated-rat model. While 11 (73%) of 15 untreated control animals had P. carinii pneumonia after 10 weeks of immunosuppression, none of the animals given 125 mg of dapsone per kg daily, weekly, biweekly, or monthly had evidence of infection. Of the 10 rats given a single dose of dapsone 23 and 50 days after immunosuppression was started, 5 (50%) had P. carinii pneumonia. When three drugs were given separately to groups of 10 rats in single doses biweekly, P. carinii pneumonia occurred in 40% of those treated with TMP-SMZ and in none of those treated with TMP-dapsone; although only 2 of those treated with pentamidine survived for evaluation, both had P. carinii pneumonia. The experiments showed that dapsone is highly effective in chemoprophylaxis for P. carinii pneumonia when given at monthly intervals or more frequently and that dapsone and TMP-dapsone are more effective than is TMP-SMZ when given at biweekly intervals. It seems reasonable to expect that biweekly doses of dapsone or TMP-dapsone would provide an effective and reasonably safe chemoprophylaxis regimen for patients at high risk for P. carinii pneumonia, and studies to test such a scheme are justifiable. Biweekly doses are preferred over monthly doses to allow for occasional inadvertent omission of doses expected from patients.

Citing Articles

Pneumocystis carinii: A review of an important opportunistic pathogen in AIDS.

Gill M, Read R Can J Infect Dis. 2012; 2(1):12-8.

PMID: 22451747 PMC: 3307398. DOI: 10.1155/1991/989875.


Pharmacokinetics of dapsone administered daily and weekly in human immunodeficiency virus-infected children.

Mirochnick M, Cooper E, McIntosh K, Xu J, Lindsey J, Jacobus D Antimicrob Agents Chemother. 1999; 43(11):2586-91.

PMID: 10543733 PMC: 89529. DOI: 10.1128/AAC.43.11.2586.


Pharmacokinetics and safety of weekly dapsone and dapsone plus pyrimethamine for prevention of pneumocystis pneumonia.

Falloon J, Lavelle J, Ogata-Arakaki D, Byrne A, Graziani A, Morgan A Antimicrob Agents Chemother. 1994; 38(7):1580-7.

PMID: 7979291 PMC: 284596. DOI: 10.1128/AAC.38.7.1580.


Use of anti-CD4+ hybridoma cells to induce Pneumocystis carinii in mice.

McFadden D, Powles M, Smith J, Flattery A, Bartizal K, Schmatz D Infect Immun. 1994; 62(11):4887-92.

PMID: 7927769 PMC: 303203. DOI: 10.1128/iai.62.11.4887-4892.1994.


Inhibition of Pneumocystis carinii dihydropteroate synthetase by sulfa drugs.

Merali S, Zhang Y, Sloan D, Meshnick S Antimicrob Agents Chemother. 1990; 34(6):1075-8.

PMID: 2203302 PMC: 171761. DOI: 10.1128/AAC.34.6.1075.


References
1.
Peters J, Gordon G, Ghoul D, TOLENTINO J, Walsh G, Levy L . The diposition of the antileprotic drug dapsone (DDS) in Philippine subjects. Am J Trop Med Hyg. 1972; 21(4):450-7. DOI: 10.4269/ajtmh.1972.21.450. View

2.
Hughes W, Kim H, Price R, Miller C . Attempts at prophylaxis for murine Pneumocystis carinii pneumonitis. Curr Ther Res Clin Exp. 1973; 15(8):581-7. View

3.
Western K, Norman L, Kaufmann A . Failure of pentamidine isethionate to provide chemoprophylaxis against Pneumocytis carinii infection in rats. J Infect Dis. 1975; 131(3):273-6. DOI: 10.1093/infdis/131.3.273. View

4.
Hughes W, Kuhn S, Chaudhary S, Feldman S, Verzosa M, AUR R . Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977; 297(26):1419-26. DOI: 10.1056/NEJM197712292972602. View

5.
Peters J, Murray Jr J, Gordon G, GELBER R . Dapsone in saliva and plasma of man. Pharmacology. 1981; 22(3):162-71. DOI: 10.1159/000137486. View